PPARG and breast carcinoma: Western blot analysis shows that treatment with subeffective doses of γ-tocotrienol (2 μM), the PPARγ agonist, rosiglitazone (3.2 μM), alone had no significant effect on COX-2 and PGDS levels in vehicle-treated and scrambled RNA transfected MCF-7 (Figure 9(a)) and MDA-MB-231 (Figure 9(b)) breast cancer cells.